皮肤冠状动脉干预后AF患者的抗血栓管理:欧洲视角
Antonio Greco1, Claudio Laudani1, Carla Rochira1
1Azienda Ospedaliero-Universitaria Policlinico 'G. Rodolico - San Marco', University of Catania Catania, Italy.
Interventional cardiology (London, England)
|August 21, 2023
概括
管理心房 (AF) 和接受皮肤冠状动脉干预 (PCI) 的患者需要平衡抗血栓治疗. 本综述研究了降低出血风险的策略,同时预防PCI后AF患者的血栓事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 心房动 (AF) 是一种常见的疾病,需要长期口服抗凝药来预防血栓栓塞事件.
- 冠状动脉疾病经常与AF共存,通常需要皮肤冠状动脉干预 (PCI) 和双抗血小板治疗 (DAPT).
- 同时治疗AF和PCI是一个重大的临床挑战,因为需要抗凝药和DAPT,导致三重抗血栓治疗.
研究的目的:
- 分析经过PCI的AF患者中血栓性并发症的机制.
- 审查目前关于这种患者群体的各种抗血栓治疗方案的证据.
- 讨论最新的欧洲指导方针,用于管理PCI后的AF患者的抗血栓治疗.
主要方法:
- 文献综述侧重于血栓机制和抗血栓策略.
- 对临床试验数据和对三重抗血栓治疗的观察性研究的分析.
- 综合了最近欧洲心脏病学会 (ESC) 指南中的建议.
主要成果:
- 三重抗血栓治疗虽然在理论上是适用的,但显著增加出血风险.
- 像缩短三重疗法的持续时间或切换到双重疗法的策略正在研究以减轻出血.
- 有证据支持基于个体患者风险概况的定制抗血栓治疗方法.
结论:
- 在接受PCI的AF患者中优化抗血栓治疗对于平衡疗效和安全至关重要.
- 目前的指导方针建议个性化治疗策略,以尽量减少出血并发症.
- 需要进一步的研究来完善这种复杂的患者群体的最佳抗血栓治疗方案.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:28Acute Coronary Syndrome IV: Interprofessional Care
12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
01:26Angina IV: Management
11
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11
01:27Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12